Intravenous Injection of Apolipoprotein A-V Reconstituted High-Density Lipoprotein Decreases Hypertriglyceridemia in apoav −/− Mice and Requires Glycosylphosphatidylinositol-Anchored High-Density Lipoprotein–Binding Protein 1
- 1 December 2010
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 30 (12), 2504-2509
- https://doi.org/10.1161/atvbaha.110.210815
Abstract
Objective— Apolipoprotein A-V (apoA-V), a minor protein associated with lipoproteins, has a major effect on triacylglycerol (TG) metabolism. We investigated whether apoA-V complexed with phospholipid in the form of a reconstituted high-density lipoprotein (rHDL) has potential utility as a therapeutic agent for treatment of hypertriglyceridemia (HTG) when delivered intravenously. Methods and Results— Intravenous injection studies were performed in genetically engineered mouse models of severe HTG, including apoav −/− and gpihbp1 −/− mice. Administration of apoA-V rHDL to hypertriglyceridemic apoav −/− mice resulted in a 60% reduction in plasma TG concentration after 4 hours. This decline can be attributed to enhanced catabolism/clearance of very-low-density lipoprotein (VLDL), where VLDL TG and cholesterol were reduced ≈60%. ApoA-V that associated with VLDL after injection was also rapidly cleared. Site-specific mutations in the heparin-binding region of apoA-V (amino acids 186 to 227) attenuated apoA-V rHDL TG-lowering activity by 50%, suggesting that this sequence element is required for optimal TG-lowering activity in vivo. Unlike apoav −/− mice, injection of apoA-V rHDL into gpihbp1 −/− mice had no effect on plasma TG levels, and apoA-V remained associated with plasma VLDL. Conclusion— Intravenously injected apoA-V rHDL significantly lowers plasma TG in an apoA-V deficient mouse model. Its intravenous administration may have therapeutic benefit in human subjects with severe HTG, especially in cases involving apoA-V variants associated with HTG.Keywords
This publication has 32 references indexed in Scilit:
- Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studiesThe Lancet, 2010
- Plasma apolipoprotein AV levels in mice are positively associated with plasma triglyceride levelsJournal of Lipid Research, 2009
- Identification of a New Functional Domain in Angiopoietin-like 3 (ANGPTL3) and Angiopoietin-like 4 (ANGPTL4) Involved in Binding and Inhibition of Lipoprotein Lipase (LPL)Published by Elsevier BV ,2009
- The ins (cell) and outs (plasma) of apolipoprotein A-VJournal of Lipid Research, 2009
- The Acidic Domain of GPIHBP1 Is Important for the Binding of Lipoprotein Lipase and ChylomicronsPublished by Elsevier BV ,2008
- An apolipoprotein A-V gene SNP is associated with marked hypertriglyceridemia among Asian-American patients*Journal of Lipid Research, 2008
- Appraisal of hepatic lipase and lipoprotein lipase activities in miceJournal of Lipid Research, 2007
- Effects of apoA-V on HDL and VLDL metabolism in APOC3 transgenic miceJournal of Lipid Research, 2007
- Avian apolipoprotein A-V binds to LDL receptor gene family membersJournal of Lipid Research, 2007
- Glycosylphosphatidylinositol-Anchored High-Density Lipoprotein-Binding Protein 1 Plays a Critical Role in the Lipolytic Processing of ChylomicronsCell Metabolism, 2007